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Glutamine has multiple roles in brain metabolism and its concentration can be altered in various pathological
conditions. An accurate knowledge of its concentration is therefore highly desirable to monitor and study several
brain disorders in vivo. However, in recent years, severalMRS studies have reported conﬂicting glutamine concentrations
in the humanbrain. A recent hypothesis for explaining these discrepancies is that a short T2 component of the glutamine
signal may impact on its quantiﬁcation at long echo times.
The present study therefore aimed to investigate the impact of acquisition parameters on the quantiﬁed glutamine
concentration using two different acquisition techniques, SPECIAL at ultra-short echo time and MEGA-SPECIAL at
moderate echo time. For this purpose, MEGA-SPECIAL was optimized for the ﬁrst time for glutamine detection.
Based on the very good agreement of the glutamine concentration obtained between the two measurements,
it was concluded that no impact of a short T2 component of the glutamine signal was detected. Copyright © 2014
John Wiley & Sons, Ltd.
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INTRODUCTION
Glutamine (Gln) is an essential amino acid in the brain, whose
concentration is affected in several brain disorders such as hepatic
encephalopathy (1,2), a neurological complication associated with
acute and chronic liver diseases. An accurate knowledge of the Gln
concentration in the healthy brain is therefore necessary for an
early detection of abnormal Gln levels. However, in recent years,
several studies have reported conﬂicting Gln concentrations in
the human brain. On the one hand, in vitro studies have reported
Gln levels of about 4μmol/g for several brain regions (3,4), which
is in agreement with in vivo measurements of Gln made using
13C MRS (5). On the other hand, 1H MRS studies in the human brain
reported widely varying results, including Gln concentrations in a
range between 1 and 4μmol/g of wet tissue (6–13).
In an attempt to reconcile these contradictory results, a recent
study performed at a magnetic ﬁeld strength of 3 T simulated
the spectral output of several localized 1H MRS techniques in
order to evaluate the possible bias of their Gln measurement
(7). However, these simulations failed to explain the discrepancy
between previous studies (6–13). At the same time, the in vivo
results of the study obtained at relatively long echo times con-
sistently gave low Gln concentrations of about 1μmol/g. The
authors therefore suggested the possibility of an underestimation
of the Gln concentration at longer echo times due to a short T2
component. This hypothesis was supported by their own results
and those of previous 1H MRS studies that reported a tendency
to measure lower Gln concentrations when using longer echo
times (TE> 30ms) (9–11) in comparison to shorter echo time
measurements (6,12). Indeed, metabolite quantiﬁcation of spectra
obtained at longer echo times is usually performed by using either
metabolite simulations corrected with measured in vitro or in vivo
T2 relaxation times (generally assuming that Gln had a similar T2
relaxation value to other known metabolites), or by using a basis
set of measured in vitro metabolite spectra in similar conditions.
In either case, Gln quantiﬁcations assume a single T2 component
in the signal decay, which can potentially lead to the acquisition
of a smaller signal than expected at long echo times if a short T2
component is present. However, results from previous studies
have not all proved to be in agreement with the hypothesis of a
short T2 component, such as the high Gln concentrations obtained
by Prescot et al. (14) at long echo time in the human brain.
Therefore, the aim of the present study was to investigate the im-
pact of acquisition parameters on the measured Gln concentration
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using two different acquisition techniques. The ﬁrst one, SPECIAL
(15), was used with an ultra-short echo time, while the second
one, MEGA-SPECIAL (16), a J-difference editing pulse sequence
optimized for the ﬁrst time in this study for Gln detection, was used
with a relatively long echo time. Such comparisonmay in particular
help in assessing the impact of a potential short T2 component of
the Gln signal on its quantiﬁcation.
METHODS
Protocol
All experiments were carried out on an animal 26 cm diameter
horizontal-bore 14.1 T magnet (Magnex Scientiﬁc, Oxford, UK)
interfaced to a Direct-Drive console (Varian, Palo Alto, CA, USA). The
magnet was equipped with a 12 cm diameter gradient (400 mT/m
in 120μs; Magnex Scientiﬁc, Oxford, UK). A custom-made quadrature
surface coil, consisting of two geometrically decoupled (crossing at a
90° angle) 14mm diameter single loops, was used as a transceiver.
All animal experiments were conducted according to federal
and local ethical guidelines and the protocols were approved by
the local regulatory body. Measurements weremade on six healthy
female adult Wistar rats and six bile-duct-ligated (BDL) female adult
rats, an animal model of chronic hepatic encephalopathy (17) char-
acterized by high brain Gln levels at seven weeks after operation
(1,18). These rats were used to investigate whether similar results
are obtained with different brain Gln concentrations.
Rats were anesthetized with 4% isoﬂurane combined with a
mixture of air and O2, stereotaxically ﬁxed with two ear pieces
and a bite bar in a holder and placed at the isocenter of the mag-
net. Throughout the experiment, the rats were kept anesthetized
with 1.5–2% isoﬂurane. Breathing and temperature parameters
were monitored with an MR-compatible monitor system (model
1025; SA Instruments, Stony Brook, NY, USA), and animal tempera-
ture was maintained at 37.5–38.5 °C by circulating warm water.
T2-weighted multi-slice images were acquired using a fast spin
echo pulse sequence (ﬁeld of view 30 × 30mm2, data matrix
2562, slice thickness 0.8mm, effective TE =52ms and repetition
time TR = 5000ms) to image brain anatomy in order to locate
the volume of interest (VOI).
Before the MRS, the static ﬁeld homogeneity was adjusted
using ﬁrst- and second-order shims with an echo-planar imaging
version of FASTMAP (19).
To obtain a reliable local calibration of the pulse power for the
frequency selective editing pulse in MEGA-SPECIAL when the sur-
face coil was used, a novel power calibration was performed. Here,
the calibration pulse sequence consisted of a STEAM sequence, in
which an editing pulse (10ms, Gaussian shape) was inserted in the
middle of the time period between the second and third STEAM
90° RF pulse. Pulse power adjustments were performed on the
water signal. The amplitude of the editing pulse was arrayed in
order to obtain a complete nulling of the water signal when the
formation of the stimulated echo was suppressed by a perfect
90° editing pulse. To obtain the amplitude of a 180° editing pulse,
the amplitude of the 90° pulse was doubled.
Following these adjustments, J-difference edited spectra and
short echo time spectra were acquired in the same VOI in
the hippocampus of each animal (VOI = 2.2 × 3× 2.5mm3). The
hippocampus was chosen as the region of interest because it is
affected in many cerebral disorders. For example, it was shown
to be associated with cognitive impairments in an animal model
of chronic hepatic encephalopathy (20).
MEGA-SPECIAL J-difference editing spectroscopy
J-difference editing was obtained for the 1H resonances bound
to the C4-glutamate (Glu) and C4-Gln centered at respectively
2.34 ppm and 2.44 ppm via their coupling with the C3-proton
resonances of both metabolites centered at respectively 2.08ppm
and 2.11 ppm using the homonuclear J-difference editing tech-
nique MEGA-SPECIAL (16). MEGA-SPECIAL was implemented by
adding an edit-ON/edit-OFF MEGA editing scheme (21) to the
SPECIAL pulse sequence (15) as illustrated in Figure 1. During
the edit-ON acquisition, single-banded refocusing pulses (10ms
Gaussian pulse with a full width at half maximum, FWHM=150Hz)
were added to SPECIAL and applied at 2.1 ppm (at the C3-proton
resonance position) to selectively refocus the C4-Glu and Gln 1H
resonances (at respectively 2.34 and 2.44 ppm), while during the
edit-OFF acquisition no editing pulse was applied.
Simulations
In general, an optimal echo time can be chosen for weakly
coupled spin systems in order to achieve an inversion of speciﬁc
lines of the multiplets of interest during the edit-OFF acquisition.
The subtraction of both edit-ON and edit-OFF acquisitions there-
fore allows the detection of only the resonances coupled to the
selectively inverted spins, while all other non-coupled resonances,
which undergo a similar evolution during both edit-ON and edit-
OFF acquisitions, are eliminated. However, in the case of the Glu
and Gln spin systems, due to the non-equivalence of the C4
protons and their strong coupling, the determination of the optimal
echo timewas obtained by numerical simulations using the density
Figure 1. (a) Scheme of the SPECIAL pulse sequence. (b) Scheme of
the MEGA-SPECIAL pulse sequence where two frequency-selective pulses
have been added to the original SPECIAL sequence. The inversion (isis)
and editing pulses, which are applied in an alternative ON/OFF scheme
during repetitive acquisitions, are indicated by the label ON/OFF. (c) Diagram
of one acquisition cycle of the MEGA-SPECIAL sequence, which consists
of two interleaved acquisitions of the ISIS scheme that were directly
subtracted from each other, while the edit-ON and edit-OFF acquisitions
were separately stored before being subtracted.
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matrix formalism and the chemical shifts and J-coupling constants
of the Gln and Glu spin systems reported by Govindaraju et al. (22).
In the simulation, perfect signal localization was considered, while
excitation, refocusing and selective inversion pulses were all
simulated as instantaneous rotations with ideal ﬂip angles. MEGA
gradients were also omitted from the simulations. Simulations of
the edit-ON and edit-OFF spectral outputs were individually
performed before being subtracted. The pulse sequence during
the edit-OFF scan was modeled as a simple spin echo, while
two frequency selective pulses that invert only the C3-proton
resonances of Glu and Gln were added before and after the
non-selective refocusing pulse to simulate ideal editing during
the edit-ON acquisitions. Spin evolution between pulses was
described with free precession Hamiltonians that take the chemical
shift and J-coupling effects into account. The echo time was
varied between 27ms and 127ms, while the inter-pulse delay
was TE/4 (for more details see Fig. 1). The TE of 27ms was the
shortest achievable echo time. To take T2 relaxation into account
in the simulations, the simulated signal was then weighted by
an exponential function of the form eTE=T2 , where T2 values of
Gln (116ms) and Glu (89ms) measured at 9.4 T were taken from
the work of Xin et al. (23). It was shown that T2 values of
metabolites are shorter at 14.1 T than at 9.4 T (24). Since this effect
is moderate (T2 of Glu is 72ms at 14.1 T (24)), we assume that the
difference in transverse relaxation between Glu and Gln at 14.1 T is
similar to that at 9.4 T.
Experiment
To meet the conditions for an optimal echo time and efﬁciently
invert signals of protons between 2.03 and 2.13 ppm (corre-
sponding to a 60Hz range) coupled to the C4-proton resonances
of Glu and Gln, the editing 10ms Gaussian pulse with an FWHM
of 150Hz was preferred over longer ones with smaller band-
width. Since the C4 protons of Glu resonate only at a frequency
144Hz higher than the frequency of the editing pulse, their
signal was partially (about 5%) inverted by the editing pulse.
To check whether the editing efﬁciency of the Glu resonance
was signiﬁcantly reduced by this effect, spectral editing was also
performed using 15 and 20ms editing pulses for comparison
(an echo time of 45ms was used for these measurements). The
C4 protons of Gln, of which the resonance is located 200Hz down-
ﬁeld from the center of the editing pulse, were affected by less
than 2% of the editing RF pulse amplitude, which was therefore
neglected. To optimize the editing efﬁciency, an array of acqui-
sitions with frequency offsets of the editing pulse in range of
60Hz around 2.1 ppm was performed to determine the optimal
frequency offset. Finally, to avoid any excessive variability of the
edited peak amplitudes, the main magnetic ﬁeld frequency drift
was monitored and did not exceed 12Hz during acquisition.
Edited spectra were obtained after subtraction of the edit-OFF
from the edit-ON acquisitions using the acquisition parameters
summarized in Table 1. The two interleaved acquisitions of the
SPECIAL acquisition scheme were directly added to each other,
while the edit-ON and edit-OFF acquisitions were separately stored
and frequency-drift corrected before being subtracted.
Quantiﬁcation
The Gln concentration was quantiﬁed relative to the total creatine
(tCr= creatine+phosphocreatine) concentration peak at 3.03 ppm
in the unedited (edit-OFF) MEGA-SPECIAL spectrum using LCModel
(25) and a measured basis set of in vitro metabolite spectra
acquired with MEGA-SPECIAL using the same parameters as those
used for in vivo editing measurements. Basis spectra were acquired
in pure metabolite solutions in pH buffer (pH=7, T=37 °C) with a
concentration of 10mM. In addition to Glu, Gln and tCr, glutathione
(GSH) was also included in the basis set, since its resonance located
at 2.15ppm falls into the inversion band of the editing pulse,
resulting in the editing of coupled resonances that overlap with
the co-edited C2 resonances of Glu and Gln located at 3.75ppm.
Spectral quantiﬁcation was restricted from 2.1 ppm to 4.5 ppm,
which corresponds to the edited spectral region. Since co-editing
of the C4-proton resonance of Glu was obtained simultaneously
with the Gln resonance editing, the Glu peak may also be used as
a reference for Gln quantiﬁcation, provided that it is efﬁciently
edited. To conﬁrm the validity of this relative quantiﬁcation, the
Gln concentration was therefore also quantiﬁed relative to the
measured co-edited Glu concentration. No macromolecule edited
signal was taken into account in the quantiﬁcation, since nomacro-
molecule resonance that falls into the editing pulse bandwidth
(between 2 and 2.2ppm) was coupled to macromolecule reso-
nances of sufﬁcient intensity to contribute to the spectrum in the
investigated spectral region (26). To conﬁrm that edited macro-
molecule signals did not contaminate the edited Glu and Gln
signals, a metabolite-nulled spectrum was measured in vivo after
adding an adiabatic inversion pulse before the MEGA-SPECIAL
sequence. The inversion time (TI) between the inversion pulse
and the beginning of the MEGA-SPECIAL pulse sequence was set
to TI = 775ms in order to minimize Glu and Gln contributions. To
further reduce metabolite contributions, which have longer T1
values than macromolecules, the repetition time was also reduced
to 2500ms, such that the magnetization available for excitation
after repetitive acquisitions was smaller for the metabolite than
for macromolecules.
Relative intensities of the basis-set spectra were calibrated
using a phantom containing all the basis-set metabolites with
concentration 1.5mM (GSH), 8mM (creatine) and 10mM (Glu
and Gln) and using the Gln spectrum as a reference for calibra-
tion in a procedure similar to that previously described (27,28).
The calibration factor kmetab by which each basis spectrum was
multiplied was determined as follows:
kmetab ¼ cgln Smetabcmetab Sgln ;
where Smetab and Sgln correspond to the LCModel quantiﬁcation
values obtained in the calibration phantom using the non-
corrected basis-set spectra, and cmetab and cgln correspond to the
real concentration of the metabolites in the calibration phantom.
The validity of this calibration was conﬁrmed in series of buff-
ered solutions with varying Gln concentrations (1mM, 2.5mM,
5mM) as well as 10mM Glu, 8mM creatine and 1.5mM GSH.
Table 1. Summary of the acquisition parameters used for
SPECIAL and MEGA-SPECIAL acquisitions
SPECIAL MEGA-SPECIAL
Echo time [ms] 2.8 27
Repetition time [ms] 4000 4000
Number of transients 128 1024
Acquisition time [min] 9 68
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In vivo validity of the calibration supposes that the difference in
T2 relaxation between in vitro and in vivo measurements is
similar for Glu (respectively creatine) and Gln.
SPECIAL short echo time spectroscopy
In vivo short echo time spectra were acquired with SPECIAL (15) as
described previously (29). Acquisition parameters are summarized
in Table 1. In each animal, the spectral acquisition using SPECIAL
was performed right after the one performed with MEGA-SPECIAL
and in the same VOI.
Absolute quantiﬁcation of the spectra was performed using
the water signal as an internal reference. The water spectra were
acquired with the same parameters, without water suppression
and with nt = 8.
In vivo 1H spectra were processed as previously described (30).
Brieﬂy, they were frequency-drift corrected, summed and eddy-
current compensated using the water signal from the same VOI.
The experimental spectra were ﬁtted with LCModel using a simu-
lated basis set ofmetabolites and amacromolecule spectrummea-
sured in vivo using an inversion recovery sequence as described
previously (29). The metabolite basis set included alanine, ascor-
bate, aspartate, creatine, myo-inositol, gamma-aminobutyric acid,
glucose, Gln, Glu, glycine, glycerophosphocholine, GSH, lactate, N-
acetyl-aspartate (NAA), N-acetyl-aspartyl-glutamate, phosphocholine,
phosphocreatine, phosphorylethanolamine, scyllo-inositol and
taurine.
Statistical analysis
To statistically assess the potential signiﬁcant differences between
the quantiﬁcation results obtained using either SPECIAL or MEGA-
SPECIAL, a paired Student t-test, which paired the quantiﬁcation
results obtained in the same VOI, was performed between the
quantiﬁcation results obtained with the two acquisition methods.
RESULTS
Based on numerical simulations, the best echo time for editing the
C4-proton Gln resonancewas determined to be 27ms (Fig. 2), which
was achieved by decreasing the editing RF pulse length to 10ms.
To assess the frequency selectivity of the 10ms editing pulse
and a potential signal loss of the C4-proton resonance of Glu
located near the editing pulse, a comparison of the editing efﬁ-
ciency obtained using editing pulses of 10, 15 and 20ms was
performed. No observable signal loss of the edited Glu (or Gln)
resonance was detected when using the 10ms pulse instead of
15 and 20ms pulses (data not shown), implying that a sufﬁcient
frequency selectivity was obtained to edit the C4-proton reso-
nances of Gln and Glu simultaneously.
The efﬁcient spectral editing of the Glu and Gln resonances was
furthermore conﬁrmed by their consistent detection in edited spec-
tra (Fig. 3). The GSH C4-proton resonance was also consistently de-
tected. The high spectral dispersion obtained at 14.1 T furthermore
allowed the clear separation of the three resonances. A residual
NAA signal at 2.01ppm was observed in the edited spectrum (not
shown), attributed to the partial saturation of the NAA resonance
during the edit-ON scan. However, since the NAA residual was
judged to be sufﬁciently distant from the C4-proton resonances
of Glu and Gln, conﬁrmed by a ﬂat ﬁt residual in the frequency
range of interest, the NAA signal was not taken into account.
Figure 2. Simulations of the difference spectra of the Gln and Glu signals
obtained at different echo times with the J-difference editing pulse
sequence MEGA-SPECIAL by subtracting simulated edit-ON and edit-OFF
spectra. The maximal amplitude of the Gln (and Glu) signal was obtained
at a TE of 27ms.
Figure 3. From top to bottom: in vivo edited 1H spectra obtained with MEGA-SPECIAL (TE = 27ms) in a healthy rat brain (left) and a BDL rat brain
(right); the edited spectra are displayed on top of their LCModel analysis, including the ﬁts of the edited metabolites Glu, Gln and GSH. In addition,
the baseline and residual of the LCModel ﬁts are also displayed.
M. CRAVEIRO ET AL.
wileyonlinelibrary.com/journal/nbm Copyright © 2014 John Wiley & Sons, Ltd. NMR Biomed. 2014; 27: 1151–1158
1154
All relevant edited resonances that contribute to the spectrum
were correctly evaluated in the LCModel quantiﬁcation process
(Fig. 3), as indicated by the ﬁt residual that showed only noise
without evidence of unassigned resonances.
Furthermore, the metabolite-nulled spectrum measured in vivo
did not exhibit any macromolecule resonances in the region of the
edited Glu and Gln resonances (Fig. 4), which is consistent with the
absence of edited macromolecule signals from this spectral region.
LCModel quantiﬁcation consistently resulted in quantiﬁcation
of Glu and Gln with Cramer–Rao lower bounds (CRLBs) lower
than 5% and 10%, respectively. GSH was also quantiﬁed, but
with lower precision (CRLB< 30%). LCModel quantiﬁcation of
the 3.03 ppm tCr peak in the unedited spectra was performed
with high precision (CRLB< 7%).
To compare the metabolite concentrations measured with
SPECIAL andMEGA-SPECIAL in the same VOI, quantiﬁcation results
obtained in the SPECIAL spectra were also evaluated using
metabolite concentration ratios between Gln and tCr or Glu, as
performed for the edited spectra obtained with MEGA-SPECIAL.
The high spectral dispersion obtained at 14.1 T enabled con-
sistent quantiﬁcation in the spectra acquired with SPECIAL of all
the metabolites included in the basis set including themetabolite
of interest, namely Gln, Glu and tCr (Fig. 5), which were quantiﬁed
with CRLB lower than 5%, indicating excellent quantiﬁcation
accuracy.
The Gln to Glu concentration ratios measured with MEGA-
SPECIAL (Cgln/Cglu = 0.28±0.04) and SPECIAL (Cgln/Cglu = 0.27±0.02)
in healthy rat brains were found to be in very good agreement
(Table 2). The standard deviation of the average Gln concentration
was, however, slightly higher when measured with MEGA-SPECIAL,
which reﬂected the lower quantiﬁcation accuracy consistent with
the higher CRLB, which was ascribed to the lower signal to noise
ratio per unit time of J-difference editing techniques.
Similar agreement on relative Gln concentrations measured
with MEGA-SPECIAL and SPECIAL was found for the BDL rats,
which expressed a higher Gln to Glu concentration ratio. This
higher Gln to Glu concentration ratio was due to an increase of
the Gln concentration in the BDL rats, as indicated by the abso-
lute Gln and Glu concentrations measured with SPECIAL (Table 2).
The higher standard deviation of the average Gln concentration
in the BDL rat group reﬂects the intra-group variability due to
Gln increases that varied between animals due to varying dis-
ease progression.
The results obtained when using the tCr concentration as a
reference for Gln quantiﬁcation were also in very good agree-
ment when measured with both MEGA-SPECIAL and SPECIAL
acquisition methods in the healthy and BDL rats.
A quantitative evaluation of the difference in the concentrations
obtained from spectra acquired with SPECIAL and MEGA-SPECIAL
gave a difference on the order of 4% in the mean values of Gln
concentration relative to Glu (and 6% for tCr), which was associ-
ated with a standard deviation of 14–16% for both quantiﬁcation
Figure 4. Top: an in vivo edited 1H spectrum acquired withMEGA-SPECIAL
at TE= 27ms is displayed with the edited resonances assigned. Bottom:
corresponding metabolite-nulled edited spectrum obtained after the
addition of an inversion pulse (TI = 775ms) that allows the nulling of
the edited metabolite signals. No resonances were detected in the
metabolite-nulled spectrum.
Figure 5. In vivo 1H spectra obtained with SPECIAL (TE = 2.8ms) in a healthy rat brain (left) and a BDL rat brain (right); the spectra are displayed on top
of their LCModel analysis.
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approaches and using both acquisition methods (Table 2). A
paired Student t-test on the Gln concentrations measured in
the spectra obtained with SPECIAL and MEGA-SPECIAL indicated
non-signiﬁcant differences between the two measurements
(p=0.5 and p=0.15 when using Glu or tCr respectively, as internal
reference concentration).
DISCUSSION
This study aimed to investigate the impact of acquisition para-
meters on the measured Gln concentration using SPECIAL at ultra-
short echo time and MEGA-SPECIAL at a moderate echo time.
The comparison of the Gln concentration measurement obtained
using both methods allowed in particular the assessment of the
potential impact of a short T2 component of the Gln signal on its
quantiﬁcation in the investigated echo time range.
To this end, this study focused on the achievement of an optimal
detection of the Gln signal. First of all, the measurement of the Gln
signal was optimized in MEGA-SPECIAL by using an optimal echo
time for the Gln signal detection, as well as by carefully calibrating
the editing pulse frequency offset and power to maximize editing
efﬁciency. While efﬁcient Glu co-editing was also shown to be fea-
sible when using optimized parameters, keeping frequency drift
within the ~12Hz range should furthermore have limited loss of
editing efﬁciency.
Second, the use of an ultra-high magnetic ﬁeld strength of
14.1 T provided an increased spectral dispersion that allowed
improved individual detection of the C4-proton resonances of
the Glu and Gln signals and their reliable individual quantiﬁca-
tion. SPECIAL and MEGA-SPECIAL acquisition methods provided
similar relative Gln concentrations, which were quantiﬁed with
low CRLB (<10%) when using either method (Table 2). The Gln
concentrations obtained at ultra-short echo time using SPECIAL
were further in excellent agreement with previous studies
performed in the healthy rat brain at high ﬁeld with similar echo
times (31–34).
Moreover, it has been observed in previous studies that an
incorrect estimation of macromolecule contribution can signiﬁ-
cantly affect the measurement of the metabolite concentration
(31,35), indicating that their accurate assessment was necessary.
The macromolecule contribution to the 1H spectra was therefore
incorporated in the quantiﬁcation as a measured basis-set signal
in the case of the SPECIAL acquisitions. In the case of the MEGA-
SPECIAL acquisitions, the possible contamination of the edited
metabolite signals with co-edited macromolecule signals was
assessed by acquiring an edited macromolecule spectrum. The
results obtained showed the absence of edited macromolecule
signals in the frequency range of interest (Fig. 4), which was in
agreement with the absence of reported J-coupling between
macromolecule resonances in the edited region and in the excita-
tion range of the editing pulse (26). This result conﬁrmed that no
macromolecule contribution had to be taken into account in the
quantiﬁcation of the edited spectra acquired with MEGA-SPECIAL.
To eliminate the presence of a quantiﬁcation bias induced by
an inaccurate editing of the C4-proton Glu resonance due to its
position close to the inversion band of the editing pulse, the
Gln concentration was also measured relative to the tCr concen-
tration. The highly consistent results obtained when using either
metabolite as a reference suggest efﬁcient and stable simulta-
neous editing of Glu along with Gln. This was further supported
by the standard deviation of the Gln concentration measure-
ment being similar when using tCr or Glu as a reference. These
results conﬁrm the validity of Gln quantiﬁcation using co-edited
Glu as a reference, and in turn the reliable quantiﬁcation of the
co-edited Glu signal.
Very good agreement was obtained between the Gln measure-
ments performed with SPECIAL at ultra-short echo time (TE=2.8
ms) and MEGA-SPECIAL at longer echo time (TE=27ms), as indi-
cated by the small and statistically non-signiﬁcant quantiﬁcation
differences obtained between the Gln concentrations measured
by the two methods, as shown in Table 2. Indeed, less than 5% dif-
ference of the Gln concentration was obtained between the two
measurements when Gln was quantiﬁed relative to Glu, and 7%
when quantiﬁed relative to tCr. Furthermore, the mean difference
of the measured Gln concentration using the two methods was of
the order of the standard deviation of the Gln concentration
measured with SPECIAL.
This agrees well with the results of statistical tests, which
showed that no measurement bias between the two methods
could be detected within experimental error. Moreover, the
difference of the Gln concentrations measured with the two
Table 2. Results of LCModel quantiﬁcation performed on the in vivo rat brain 1H spectra acquired with SPECIAL
at an echo time of 2.8ms and MEGA-SPECIAL at an echo time of 27ms.The upper part of the table presents the
relative Gln concentrations obtained with both methods, while in the bottom part the results of the quantitative
comparison between the quantiﬁcation results obtained with the two acquisition methods are summarized
Healthy rat (n= 6) BDL rat model (n= 6)
LCModel quantiﬁcation results
CGln/CGlu MEGA-SPECIAL 0.28 ± 0.04 0.72 ± 0.22
CGln/CtCr MEGA-SPECIAL 0.34 ± 0.07 0.65 ± 0.20
CGln/CGlu SPECIAL 0.27 ± 0.02 0.70 ± 0.19
CGln/CtCr SPECIAL 0.36 ± 0.03 0.70 ± 0.21
CGln SPECIAL [μmol/g] 2.75 ± 0.18 6.22 ± 1.42
CGlu SPECIAL [μmol/g] 10.15 ± 0.27 9.09 ± 0.69
CtCr SPECIAL [μmol/g] 7.68 ± 0.21 7.09 ± 0.24
Relative quantiﬁcation differences
CGln=CGluMEGASPECIALCGln=CGluSPECIAL
CGln=CGluSPECIAL
0.05 ± 0.16 0.04 ± 0.16
CGln=CtCrMEGASPECIALCGln=CtCrSPECIAL
CGln=CtCrSPECIAL
- 0.07 ± 0.14 - 0.06 ± 0.16
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acquisition methods at different echo times was similar for both
the healthy rats and the diseased rats, which were characterized
by higher brain Gln concentrations. This suggests that the
lower Gln concentration measured in the healthy brain was not
systematically biased. Furthermore, the very good agreement
obtained in this study between the two measurements of the
Gln concentration made at short and longer echo times indicates
that there is no evidence of an underestimation of the Gln
concentration at moderate echo time due to an effect of an
additional short T2 component of the Gln transverse relaxation
in in vivo conditions due to several brain compartments, as
hypothesized by Hancu and Port (7). The results of this study
are further supported by results from previous studies that
reported measured Gln concentrations in the human brain in
the higher range when using long echo times (TE> 30ms) (14).
In addition, it is of interest that the Gln concentration that we
report here for the rat brain is close to the 2.2 ± 0.4μmol/g
reported by Mekle et al. (13) for the human brain at 7 T using
the SPECIAL technique with a short echo time.
Since similar Gln concentration results were obtained when
using either SPECIAL or MEGA-SPECIAL, it also indicates that
SPECIAL appears to be as reliable as a J-difference editing pulse
sequence for measuring the Gln concentration and might there-
fore be considered as a reliable method for Gln measurement,
while having several advantages over MEGA-SPECIAL. The SPECIAL
spectroscopy, which has already been successfully implemented at
3 T and 7 T (13), provides concentrations of all the metabolites in
the neurochemical proﬁle. In addition, it gives an inherently higher
SNR per unit time compared with MEGA-SPECIAL, which suffers
from longer echo times and RF pulse imperfections.
We therefore conclude that the impact on the measured Gln
concentration of using the different acquisition techniques SPECIAL
and MEGA-SPECIAL at echo times less than 30ms is negligible and
that there is no evidence of a systematic underestimation of the
Gln concentration in the investigated echo-time range due to a
short T2 component in the transverse relaxation of the Gln signal.
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